Tax-withholding of 45,711 shares by AngioDynamics (ANGO) CEO disclosed

Rhea-AI Filing Summary

AngioDynamics Inc. President and CEO James C. Clemmer reported five exempt dispositions of common stock from July 16–20, 2026. In total, 45,711 shares were withheld at per-share prices including $14.1400, $13.5100, and $13.7100 to satisfy tax withholding obligations on previously granted restricted stock units as they vested.

Insider Trade Summary

Net Seller: 45,711 shares

Net Sell 5 txns

Insider Clemmer James C

Role President and CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F5	4,223	$13.71	$58K
Tax Withholding	Common Stock F3	11,764	$13.51	$159K
Tax Withholding	Common Stock F4	487	$13.51	$7K
Tax Withholding	Common Stock F2	10,649	$13.51	$144K
Tax Withholding	Common Stock F1	18,588	$14.14	$263K

Holdings After Transaction: Common Stock — 836,818 shares (Direct)

Footnotes (5)

1. F1. The exempt disposition of 18,588 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.
2. F2. The exempt disposition of 10,649 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.
3. F3. The exempt disposition of 11,764 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.
4. F4. The exempt disposition of 487 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2024.
5. F5. The exempt disposition of 4,223 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

Key Figures

Total shares withheld for taxes: 45,711 shares Shares withheld on July 16, 2026: 18,588 shares Shares withheld on July 17, 2026: 10,649 shares +4 more

7 metrics

Total shares withheld for taxes 45,711 shares ExercisePriceOrTaxLiabilityShares across five F-code dispositions in July 2026

Shares withheld on July 16, 2026 18,588 shares Exempt disposition to satisfy tax withholding on RSUs granted July 16, 2025

Shares withheld on July 17, 2026 10,649 shares Exempt disposition to satisfy tax withholding on RSUs granted July 17, 2024

Shares withheld on July 19, 2026 11,764 shares and 487 shares Exempt dispositions for tax withholding on RSUs granted July 19, 2023 and July 19, 2024

Shares withheld on July 20, 2026 4,223 shares Exempt disposition to satisfy tax withholding on RSUs granted July 20, 2022

Highest withholding price $14.1400 per share Price for 18,588-share tax-withholding disposition dated July 16, 2026

Other withholding prices $13.5100 and $13.7100 per share Per-share values used for remaining July 2026 tax-withholding dispositions

Key Terms

exempt disposition, tax withholding obligations, restricted stock units, pre-determined vesting

4 terms

exempt disposition financial

"The exempt disposition of 18,588 shares of common stock of AngioDynamics"

tax withholding obligations financial

"was made to satisfy tax withholding obligations in connection with the pre-determined vesting"

restricted stock units financial

"pre-determined vesting of shares underlying restricted stock units granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

pre-determined vesting financial

"in connection with the pre-determined vesting of shares underlying restricted stock units"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/21/2026 - 08:17 PM Accepted by SEC EDGAR 07/21/2026 - 08:17 PM Learn about SEC filing dates

FAQ

What insider stock activity did AngioDynamics (ANGO) report for its CEO?

AngioDynamics reported that CEO James C. Clemmer had 45,711 common shares withheld in July 2026. These were coded as exempt dispositions to cover tax withholding obligations arising from the vesting of previously granted restricted stock units.

Were the AngioDynamics (ANGO) CEO’s reported transactions open-market sales?

No. The Form 4 describes exempt dispositions under transaction code F, meaning shares were withheld to pay taxes. Footnotes state the shares satisfied tax withholding obligations linked to pre-determined vesting of restricted stock units granted in 2022–2025.

How many AngioDynamics (ANGO) shares were withheld for taxes on each date?

Reported withholding covered 18,588 shares on July 16, 10,649 on July 17, 11,764 and 487 on July 19, and 4,223 on July 20, 2026. Each transaction related to vesting restricted stock units from earlier grant dates.

What prices were used for the AngioDynamics (ANGO) CEO’s tax-withholding dispositions?

The common shares withheld for CEO James C. Clemmer’s tax obligations were valued at $14.1400, $13.5100, and $13.7100 per share. These per-share values correspond to the individual exempt disposition entries reported for the July 2026 withholding events.

Which AngioDynamics (ANGO) equity awards triggered the CEO’s tax-withholding events?

The tax-withholding dispositions relate to vesting of restricted stock units granted to the CEO on July 20, 2022, July 19, 2023, July 17, 2024, July 19, 2024, and July 16, 2025, as each award reached a pre-determined vesting date.

Does the AngioDynamics (ANGO) CEO’s Form 4 indicate trades under a 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan. The transactions are characterized instead as exempt dispositions for tax withholding tied to scheduled vesting of restricted stock units, rather than discretionary market trades.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clemmer James C

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		F		18,588(1)	D	$14.14	863,941	D
Common Stock	07/17/2026		F		10,649(2)	D	$13.51	853,292	D
Common Stock	07/19/2026		F		11,764(3)	D	$13.51	841,528	D
Common Stock	07/19/2026		F		487(4)	D	$13.51	841,041	D
Common Stock	07/20/2026		F		4,223(5)	D	$13.71	836,818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The exempt disposition of 18,588 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

2. The exempt disposition of 10,649 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

3. The exempt disposition of 11,764 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

4. The exempt disposition of 487 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2024.

5. The exempt disposition of 4,223 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

	/s/ Lawrence T. Weiss, as Attorney in Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)